Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Desert King International is a premier global supplier and manufacturer of natural extracts derived from Yucca schidigera and Quillaja saponaria. The company is widely recognized for its expertise in the production of high-purity saponins, particularly QS-21, which is a vital adjuvant used in blockbuster vaccines such as GSK's Shingrix and Mosquirix. Desert King operates a vertically integrated supply chain with significant harvesting and processing facilities in Mexico and Chile, ensuring the sustainability and traceability of its raw materials. In addition to its pharmaceutical business, the company serves the animal nutrition, food and beverage, and personal care industries with natural foaming agents and emulsifiers. Their advanced purification technologies allow for the production of pharmaceutical-grade ingredients that meet stringent global regulatory standards. As a key player in the vaccine supply chain, Desert King continues to innovate in the field of immunological adjuvants and natural surfactants.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Desert King International.